資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/32515
|
| 標題: | Statin use and Vital Organ Failure in Patients With Asthma-Chronic Obstructive Pulmonary Disease Overlap: A Time-Dependent Population-Based Study |
| 作者: | Yeh, Jun-Jun(葉俊濬)
Syue, Shih-Huei
Lin, Cheng-Li
Hsu, Chung Y.
Shae, Zonyin
Kao, Chia-Hung |
| 貢獻者: | Ditmanson Med Fdn Chia Yi Christian Hosp, Dept Famiy Med
Chia Nan Univ Pharm & Sci, Dept Childhood Educ & Nursery
China Med Univ, Coll Med
Mei Ho Univ, Dept Nursing
China Med Univ Hosp, Management Off Hlth Data
China Med Univ, Coll Med, Grad Inst Biomed Sci
China Med Univ, Coll Med, Sch Med
Asia Univ, Dept Comp Sci & Informat Engn
China Med Univ Hosp, Dept Nucl Med
Asia Univ, Dept Bioinformat & Med Engn |
| 關鍵字: | asthma-chronic obstructive pulmonary disease overlap (ACO)
hepatic failure
renal failure
heart failure
respiratory failure |
| 日期: | 2019-08 |
| 上傳時間: | 2020-07-29 13:48:07 (UTC+8) |
| 出版者: | FRONTIERS MEDIA SA |
| 摘要: | Objective: The effects of statins on the risk of hepatic, renal, respiratory, and heart failure among patients with asthma-chronic obstructive pulmonary disease overlap (ACO) have not been reported. Design: Time-dependent population-based study. Setting: Patient data from 2000 to 2010 were retrieved from the Taiwan National Health Insurance Research Database. Patients: We divided patients with ACO into cohorts of statin use (N = 1,211) and nonuse (N = 7,443). Measurements and Main Results: The cumulative incidence rates of hepatic, renal, respiratory, and heart failure were analyzed through Cox proportional regression analysis with time-dependent variables. After adjustment for multiple confounding factors, including age, sex, comorbidities, and medications [statins, inhaled corticosteroid (ICS), or oral steroid (OS)], the adjusted hazard ratios (aHRs) [95% confidence intervals (CIs)] for hepatic, renal, respiratory, and heart failure were 0.50 (0.40-0.64), 0.49 (0.38-0.64), 0.61 (0.27-2.21), and 0.47 (0.37-0.60), respectively. The aHRs (95% Cls) for statin use with [ICS, OS] for hepatic, renal, and heart failure were [0.36 (0.20-0.66), 0.52 (0.39-0.70)]; [0.82 (0.51-1.34), 0.46 (0.33-0.63)]; and [0.66 (0.40-1.07), 0.48 (0.37-0.64)], respectively. Conclusions: The ACO cohort with statin use exhibited lower risk of hepatic, renal, and heart failure than any other cohort, regardless of age, sex, comorbidities, or ICS or OS use. Regarding the combined use of statins and ICS, the risks of hepatic failure were lower. For the combined use of statins and OS, hepatic, renal, and heart failure were less frequent. |
| 關聯: | Frontiers in Pharmacology, v.10, 889 |
| 顯示於類別: | [嬰幼兒保育系] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| 10.3389-fphar.2019.00889.pdf | | 1031Kb | Adobe PDF | 358 | 檢視/開啟 | | index.html | | 0Kb | HTML | 1310 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
